Search company, investor...
Search

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

cubist.com

Founded Year

1992

Stage

Acquired | Acquired

Total Raised

$13M

Valuation

$0000 

About Cubist Pharmaceuticals

Cubist Pharmaceuticals is a pharmaceutical company developing novel antimicrobial drugs.

Cubist Pharmaceuticals Headquarters Location

65 Hayden Avenue

Lexington, Massachusetts, 02421,

United States

781-860-8660

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Cubist Pharmaceuticals Patents

Cubist Pharmaceuticals has filed 65 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/21/2014

7/19/2016

Ion channels, G protein coupled receptors, Membrane biology, Analgesics, Neurological disorders

Grant

Application Date

1/21/2014

Grant Date

7/19/2016

Title

Related Topics

Ion channels, G protein coupled receptors, Membrane biology, Analgesics, Neurological disorders

Status

Grant

Latest Cubist Pharmaceuticals News

Xilio Therapeutics Appoints Timothy D. Hunt as Chief Culture and Corporate Affairs Officer

Oct 12, 2021

10/12/2021 | 06:31am EDT Message : *Required fields Xilio Therapeutics, Inc. (Xilio) a biotechnology company developing tumor-selective immuno-oncology therapies for patients with cancer, today announced that Timothy D. Hunt has been appointed as the company’s chief culture and corporate affairs officer. In this role, Mr. Hunt will serve as a member of the executive team and will oversee human resources, communications and other strategic initiatives. “Tim is an experienced company-builder with an extensive background in growing and scaling clinical-stage organizations, and I am delighted he is joining Xilio,” said René Russo, Pharm. D., president and chief executive officer of Xilio. “With one program in the clinic and a second clinical-stage program anticipated this year, Tim’s leadership will be vital as we continue to build out our team, advance our strong culture and effectively manage communications to our key external stakeholders.” “Leveraging its GPS platform, Xilio has developed a pipeline of immuno-oncology product candidates designed to provide deep and durable clinical responses that have the potential to offer significant advantages over currently available treatments,” said Mr. Hunt. “The progress made in a short amount of time is impressive, and I am pleased to join this driven and innovative team as we work to advance our lead programs for patients with cancer.” Mr. Hunt brings more than 20 years of biotechnology experience to Xilio, most recently serving as chief corporate affairs officer at Editas Medicine, Inc. (Editas) where he oversaw the human resources, market development and early-stage commercial planning, policy and government affairs, and corporate communications functions from 2016 to 2020. Prior to Editas, he was senior vice president of public affairs for Cubist Pharmaceuticals, Inc. (Cubist), a biotechnology company focused on the development and commercialization of infectious disease therapeutics, from 2011 until its acquisition by Merck Research Laboratories in 2015. Before joining Cubist, Mr. Hunt was vice president of public affairs at Biogen Inc. He currently serves as a member of the Board of Directors of the non-profit organization Life Sciences Cares and as chair of the Ethics Committee of the American Society of Gene and Cell Therapy. Mr. Hunt received a B.A. in history and philosophy from Boston College and a J.D. from the Columbus School of Law at the Catholic University of America. About Xilio Therapeutics Xilio Therapeutics is a privately-held biotechnology company focused on harnessing the immune system to achieve deep and durable clinical responses to improve the lives of patients with cancer. The company is using its proprietary geographically precise solutions (GPS) platform to rapidly engineer novel molecules, including cytokines and other biologics that are designed to optimize their therapeutic index. These molecules are designed to localize activity within the tumor microenvironment without systemic effect, resulting in the potential to achieve enhanced anti-tumor activity. Xilio is building a pipeline of wholly owned, tumor-selective, GPS-enabled cytokine and checkpoint inhibitor product candidates, including XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody; XTX202, a tumor-selective IL-2; XTX301, a tumor-selective IL-12; and XTX401, a tumor-selective IL-15. For more information, please visit www.xiliotx.com . View source version on businesswire.com: https://www.businesswire.com/news/home/20211012005282/en/ © Business Wire 2021

  • When was Cubist Pharmaceuticals founded?

    Cubist Pharmaceuticals was founded in 1992.

  • Where is Cubist Pharmaceuticals's headquarters?

    Cubist Pharmaceuticals's headquarters is located at 65 Hayden Avenue, Lexington.

  • What is Cubist Pharmaceuticals's latest funding round?

    Cubist Pharmaceuticals's latest funding round is Acquired.

  • How much did Cubist Pharmaceuticals raise?

    Cubist Pharmaceuticals raised a total of $13M.

  • Who are the investors of Cubist Pharmaceuticals?

    Investors of Cubist Pharmaceuticals include Merck & Co., Hancock Capital Management, Investors Bank And Trust Company, Clarion Capital Partners, Metzler Asset Management GmbH and 23 more.

  • Who are Cubist Pharmaceuticals's competitors?

    Competitors of Cubist Pharmaceuticals include Biocytogen, Achillion Pharmaceuticals, Array Biopharma, PhaseBio Pharmaceuticals, Kythera Biopharmaceuticals and 13 more.

You May Also Like

S
Sarossa Capital

Sarossa, formerly Antisoma, is an investment holding and management company whose principal activity is investment in and growth and development of businesses which present opportunities for value creation.

G
Glycotope

Glycotope is a biopharmaceutical company in glycomics and its application for development of biopharmaceuticals.

u
ugichem

ugichem is developing antisense drugs based on its proprietary Ugimer platform for unmet medical needs in immune-mediated inflammatory diseases (IMID). Ugimers overcome the shortcomings of standard antisense technologies or RNAi. In contrast, Ugimers are not derived from natural nucleic acids but are based on the peptide nucleic acid (PNA) backbone and carry specific side chains for improved delivery, efficacy and specificity. This innovative design provides Ugimers with unique biopharmaceutical properties allowing them access to previously inaccessible organs, cells and cellular compartments, including the immune system. Moreover, Ugimers are the first and only antisense drugs that have efficacy in mitochondria.

A
Angel Biotechnology

Angel Biotechnology Holdings PLC (AIM: ABH) is a world class, contract biomanufacturing company offering process development services and pre-GMP and cGMP manufacturing to support biotechnology and pharmaceutical companies worldwide. Angel's principal activity is the manufacture and supply of materials for use in early stage drug development and pre-clinical studies, along with drug product and CMC documentation for Phases I, II and III clinical trials and the manufacture of licensed drugs or vaccines. nnAngel is managed by a team that has more than 100 years' combined experience in pharmaceutical and biopharmaceutical manufacture, gained in companies such as Glaxo and Serologicals Inc. nnAngel operates out of Pentlands Science Park, near Edinburgh.

C
Clal Biotechnology Industries

Clal Biotechnology Industries is a public investment firm targeting pre-clinical, seed, start-up, early venture, emerging growth and growth capital stages of financing that was founded in 1998 and based in Tel Aviv, Israel. Clal primarily invests in biopharmaceutical and biotech companies. Generally, Clal Biotechnogy Industries looks to invest up to $10 million per company and prefers to be lead investor and take a board seat. It also seeks to take a majority share in its portfolio companies.

C
Celgen Biopharmaceuticals

Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.